A two-week clinical evaluation of the safety of Systane® Ultra in contact lens-wearing patients by Kading, David
© 2010 Kading, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology
Clinical Ophthalmology 2010:4 27–32 27
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
O R i g i n A L   R e s e A R C h
A two-week clinical evaluation of the safety 
of systane® Ultra in contact lens-wearing patients
David Kading
specialty eyecare group,  
Kirkland,   WA, UsA
Correspondence: Dave Kading 
11830 ne 128th st, suite 1,  
Kirkland,   WA 98034, UsA 
Tel +1 425 821 8900 
Fax +1 425 814 9782 
email doctorkading@gmail.com.
Objective: To evaluate the safety of Systane® Ultra Lubricant Eye Drops (test solution) in contact 
lens wearers. A currently marketed contact lens rewetting drop was the control solution.
Participants: This investigator- and patient-masked, single-site, randomized, and prospective 
study involved 45 successful contact lens wearers.
Methods: Eligible subjects’ baseline biomicroscopy findings, visual acuity, and corneal staining 
score were recorded. Subjects received either the test or control solution with masked label-
ing. Subjects were instructed to instill their assigned solution in both eyes: 15 minutes prior 
to lens insertion, at least one drop during lens wear and another drop immediately following 
lens removal. After 14 days, biomicroscopy results, visual acuity, and corneal staining score 
were recorded.
Results: No adverse events were documented for either the test or the control solution. For 
subjects using Systane® Ultra, no statistically significant change was detected in visual acuity 
(= 0.7667) or corneal staining score (P = 1.000). For subjects using the control solution, 
the change in visual acuity (P = 0.0011, mean difference = 1.70 ± 3.22 standard deviation) 
was not clinically relevant and there was no significant change in corneal staining score 
(P = 0.5413).
Conclusions: This clinical study provided evidence of safety and compatibility of Systane® 
Ultra Lubricant Eye Drops in contact lens wearers.
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Contact lens wear continues to be a popular method of vision correction, with an 
estimated 35 million contact lens wearers in North America.1 New lens polymers that 
promote ocular health, longer-lasting comfort, and flexible wearing modalities attract 
new wearers and contribute to the success of this form of vision correction.
Despite the fact that the contact lens market is growing, a concerning number of 
contact lens wearers drop out of contact lens wear every year. While inconvenience, 
ocular hyperemia, blurry or inconsistent vision as well as cost are all factors in an 
individual’s decision to discontinue lens wear, contact-lens induced dryness and dis-
comfort are consistently reported as the most common reasons for lens abandonment.2,3 
Pritchard and colleagues found 12% of contact lens patients discontinued lens wear 
within five years of the initial fitting due to dryness and discomfort symptoms.4
For patients, ‘discomfort’ and ‘dryness’ are often synonymous, with a high cor-
relation between comfort and dryness ratings for both symptomatic and asymptomatic 
patients.1 Among current contact lens wearers, approximately 50% experience dry eye 
symptoms to varying degrees. And while, in most cases, the dryness is not frequent Clinical Ophthalmology 2010:4 28
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or noticeable enough for wearers to remove their lenses, as 
many as 20% have symptoms severe enough for them to 
reduce their wearing time.5,6 In a study of 1,054 patients 
surveyed on dry eye symptoms (including 367 contact lens 
wearers), the authors report an even higher incidence of 
ocular dryness. Of the contact lens wearers surveyed, 77% 
reported some degree of dryness symptoms (compared to 
nearly 44% of nonlens wearers). In addition, 70% to 80% 
of the contact lens wearers reported frequent eye discomfort 
and visual changes.7,8
The reported effects of contact lenses on the tear film may 
precipitate dry eye symptoms. A reduction in the pre-lens tear 
film lipid layer and an increase in tear film evaporation are 
associated with contact lens wear.9–13 These changes result in 
increased tear film osmolality14,15 affecting tear film stability 
and tear break up time. This disruption of the tear film in 
contact lens wearers is associated with reduced functional 
visual acuity,16,17 decreased wear time4 and an increased risk 
of ocular surface desiccation.18,19
Artificial tear supplements are widely used to relieve 
dry eye symptoms and sustain ocular comfort during lens 
wear.20 Begley and colleagues report that 47% of contact 
lens wearers reported the use of rewetting drops but indi-
cated that these provided only moderate relief.7 Despite their 
viscosity-enhancing ingredients, instilled drops tend to have 
a short residency time and require frequent re-instillation 
throughout the day.
Systane® Ultra Lubricant Eye Drops (Alcon Laboratories, 
Inc., Fort Worth, TX, USA) is a new-generation ocular lubri-
cant for the treatment of dry eye. Clinical results show that 
Systane® Ultra provides long lasting relief from dry eye.21,22
The loosely cross-linked, droppable gel, after instillation 
in the eye, reduces in viscosity with the first blink allow-
ing even distribution over the ocular surface. Subsequent 
interaction with the divalent ions and mucin in the tear film 
facilitates the development of a viscoelastic, gel-matrix with 
shear thinning and bioadhesive properties. The gel-matrix 
promotes retention of the active demulcents for tear film sta-
bility, lubrication, and protection of the ocular surface.23,24
The clinical benefits of Systane® Ultra in treating dry eye 
together with its viscoelastic properties may offer advantages 
for contact lens wearers in the prevention of contact lens-
related dry eye.
The purpose of this clinical study is to evaluate the safety 
of Systane® Ultra in a group of successful contact lens wear-
ers compared with that of a currently available contact lens 
rewetting drop: Sensitive Eyes® Rewetting Drops (Bausch and 
Lomb, Rochester, NY, USA).
Methods
Materials
The test solution was Systane® Ultra Lubricant Eye Drops 
containing polyethylene glycol 400 (PEG) and propylene 
glycol (PPG) as demulcents. Bausch and Lomb Sensitive 
Eyes® Rewetting Drops, an isotonic aqueous solution with 
low viscosity, currently marketed as a drop to reduce con-
tact lens-related dryness symptoms, was used as the control 
solution.
study population
This prospective, randomized, double-masked, single site 
clinical study of two weeks duration enrolled 45 successful 
contact lens wearers aged between 18 and 65 years wearing 
either once or twice per month planned-replacement soft 
contact lenses (SCL) or gas permeable (GP) lenses. As 
a prerequisite for enrollment, subjects were required to 
have contact lens acuity of 20/30 or better in each eye, 
be in good health and to continue any pre-enrollment 
systemic medication regimens during the study. Atten-
dance at all clinical study visits and completion of 
study questionnaires was also required. There were no 
restrictions to the currently employed contact lens care 
regimen, rewetting drop usage or lens type (planned 
replacement soft or GP).
Exclusion criteria included a history of allergy to any 
study product ingredient and current use of any topical eye 
medications (with the exception of rewetting drops or artifi-
cial tear products). Subjects who had modified their systemic 
medications within 30 days prior to enrollment were excluded 
as were subjects with significant active corneal, eyelid or 
anterior segment infection or inflammation.
The primary objective was to evaluate safety with the 
use of Systane® Ultra in contact lens wearers. A compari-
son to a currently available contact lens rewetting drop was 
included as a control. Safety was established by assessment 
of visual acuity, corneal staining, biomicroscopy examina-
tion and adverse events. The clinical study was performed 
in compliance with the ethical principles of the Declaration 
of Helsinki and written informed consent was obtained from 
all patients enrolled.
Procedures
At the first screening visit (Visit 1 – screening), after a 
subject’s preliminary eligibility was established, demographic 
information, medical history and current usage of systemic 
medication and any topical ocular drops (including rewetting 
drops, artificial tears and Restasis® [Allergan, Inc., Irvine Clinical Ophthalmology 2010:4 29
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CA, USA]) was recorded. Baseline measurements of safety 
parameters, including distance visual acuity with contact 
lenses and corneal staining score were recorded. Biomicros-
copy findings (lids/eyelashes, cornea, and conjunctiva) were 
recorded as either normal or abnormal.
Subsequently, patients were randomly dispensed either 
Systane® Ultra or Sensitive Eyes. Both the test and the 
control solutions were dispensed in 10 and 15 mL bottles 
with sterile closures and masked labeling supplied in pre-
numbered kits. Patients were educated in the correct admin-
istration of the drops and instructed to instill 1–2 drops of 
the assigned lubricating eye drop in both eyes on a daily 
basis, approximately 15 minutes prior to contact lens 
insertion, at least one drop during the lens wear period and 
immediately following lens removal. Written instructions 
were provided.
Follow up visits (Visit 2 – follow up) were conducted 
two weeks after the first screening visit. Results for distance 
visual acuity with contact lenses and corneal staining score 
were recorded. Any changes in biomicroscopy assessment 
of the lids, cornea, and conjunctiva were recorded. Biomi-
croscopy findings (lids/eyelashes, cornea, and conjunctiva) 
were also recorded.
Distance visual acuity
Contact lens visual acuity was measured for distance. Acuities 
were measured using a Snellen letter chart. Testing was 
conducted monocularly under photopic lighting conditions 
(85 cd/m2).
Biomicroscopy
Subjects were assessed for corneal staining and any abnormal 
findings associated with the lids, cornea, and conjunctiva. 
Corneal staining was graded using the NEI staining grid 
in which a score of 0–3 (0 = normal and 3 = severe) was 
assigned to each of five corneal regions (nasal, central, tem-
poral, inferior, and superior) with a maximum total score of 
15 (Figure 1).10
Adverse events
Adverse events were considered to be any unfavorable or 
unexpected medical occurrence in a subject using the test 
or control solutions. For enrolled subjects, any change from 
baseline in the clinical findings deemed unfavorable, was 
considered an adverse event and recorded. Serious adverse 
events, whether related to use of the respective solution or 
not, required discontinuation of that solution and appropriate 
medical treatment.
statistical methods
Within-subject before and after treatment comparison was 
conducted using paired t-test. Student’s t-test was used for 
between-group comparisons in numeric. All tests were two-
sided with the confidence level set to 95%.
Results
Forty-five subjects were enrolled and successfully com-
pleted the study. There were 14 (31%) males and 31 (69%) 
females ranging in age from 21 to 53 years (mean, 31.2 years; 
standard deviation [SD], 8.1). Subject ethnicity was White 
(n = 40. 89%), Asian (n = 2), Hispanic (n = 1), and two were 
unspecified. Twenty-three subjects were randomized into the 
Systane® Ultra group, and 22 into the Sensitive Eyes® group. 
The two treatment groups were comparable in demographic 
background.
Within-subject changes in visual acuity and the corneal 
staining score are presented in Table 1. No significant changes 
in visual acuity were observed in the Systane® Ultra group 
(P = 0.7667). In the Sensitive Eyes® group (P = 0.0011), an 
improvement in visual acuity from 22.27 (SD, 3.32) to 
20.57 (SD, 1.61) (P = 0011) was observed, although this 
is not considered clinically relevant.
Figure 1 Corneal staining was graded in each of five corneal zones using the 
nei grid (superior, nasal, central, inferior, temporal).
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0 – Normal, negative slit lamp findings
1 – Mild, superficial stippling
2 – Moderate, punctate staining including superficial abrasion of the cornea
3 – Severe, abrasion or corneal erosion, deep corneal abrasion or recurrent erosion Clinical Ophthalmology 2010:4 30
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Adverse events
There were no adverse events reported from this clinical 
study. No clinically significant abnormal biomicroscopy 
findings were reported during follow-up in either group.
Discussion
The safety of Systane® Ultra Lubricant Eye Drops in 
contact lens wearers was evaluated in this clinical study 
involving 45 successful lens wearers. Systane® Ultra was 
well tolerated and demonstrated a favorable safety profile 
when administered topically at least three times a day in 
conjunction with contact lens wear. Ocular assessments 
including visual acuity and corneal staining score showed 
no significant treatment-related changes and there were no 
serious ocular or systemic adverse events reported. The 
safety profile of Systane® Ultra was comparable to that of 
a currently marketed contact lens rewetting drop. These 
clinical findings add support for the use of Systane® Ultra 
by contact lens wearers.
These results provide contact lens wearers with increased 
confidence in the use of Systane® Ultra during lens wear 
for the treatment of contact lens-related dry eye. Given that 
dryness is the most frequent symptom in approximately 
75% of contact lens wearers25,26 and contact lens wear can 
increase the frequency and severity of pre-existing dry eye,25 
there is considerable opportunity for contact lens wearers to 
experience the relief of an effective dry eye therapy. Additional 
clinical benefits of Systane® Ultra in dry eye patients, namely, 
immediate patient comfort, enhanced lubrication and minimal 
blur on instillation,27 are likely to also apply to contact lens 
wearers. Conclusions drawn by Christensen and colleagues 
regarding the overall safety profile of an hydroxypropyl guar 
(HP-Guar)-containing lubricant eye drop in prior research28 
add support to the findings of the current study.
Systane® Ultra Lubricant Eye Drops is a new product in 
the Systane® family of dry eye therapies. It is an aqueous 
solution comprising PEG (0.4%) and PPG (0.3%) as demul-
cents and incorporating the benefits of HP-Guar as a gelling 
agent. The above-mentioned ingredients have a history of 
use in ophthalmic preparations as well as contact lens care 
products and have demonstrated compatibility with the ocular 
surface.28 In addition, Systane® Ultra includes borate and 
sorbitol as key ingredients. Sorbitol, a water soluble, nonionic 
compound, interacts with borate29 to control viscosity in the 
bottle for optimal delivery in the eye. The presence of sorbitol 
facilitates the even distribution of the eye drop over the ocular 
surface upon instillation.
Ketelson and colleagues27 demonstrated that this increase 
in viscoelasticity on-eye and between blinks correlates with 
a significant reduction in friction. This finding has implica-
tions for contact lens wear whereby the reduction in friction 
between the lens and the lids has the potential to improve 
lens-wearing comfort. Similar reductions in friction have 
been reported by Meyer and colleagues in connection with 
a similar HP-Guar containing ocular lubricant from within 
the Systane® family.30 In addition, a study involving contact 
lens wearers showed that the use of an HP-Guar-containing 
ocular lubricant was associated with improved comfortable 
lens-wearing times and an improved overall lens-wearing 
experience.31
The success of contact lens wear depends on the integrity 
and stability of the tear film. While Systane® Ultra is not 
considered to be used a re-wetting solution for contact lens 
wearers, Systane® Ultra is designed to rebuild the tear film for 
long-term lubrication and extended protection of the ocular 
surface.22 A good tear film covering a contact lens is thought to 
provide comfort, vision, lubrication, prevent surface drying, 
remove debris, and counter infection.6 Chalmers and Begley8 
Table 1 Within-subject changes in visual acuity (snellen best-corrected visual acuity) and the sum staining score
Time Systane® Ultra (n = 46 eyes) Sensitive Eyes® (n = 44 eyes) P-value1
  Mean (SD) Range Mean (SD) Range  
Baseline
  Visual acuity 21.20 (2.40) 20–30 22.27 (3.32) 20–30 0.0826
  sum staining score 0.33 (0.63) 0–2 0.43 (0.76) 0–2 0.4746
Follow-up
  Visual acuity 21.30 (2.46) 20–30 20.57 (1.61) 20–25 0.0951
  sum staining score 0.33 (0.67) 0–3 0.55 (1.02) 0–5 0.2342
Notes: P-values of student’s t-test for between-group comparison. Per paired t-test, no statistically significant within-subject changes were detected for the Systane® Ultra 
group for visual acuity (P = 0.7667) or sum staining scores (P = 1.0000). For the Sensitive Eyes group, the changes in visual acuity were statistically significant (P = 0.0011, mean 
difference = 1.70 ± 3.22 sD), but not the sum staining score (P = 0.5413). Clinically, a change of 1.70 in visual acuity is not considered clinically relevant.Clinical Ophthalmology 2010:4 31
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claim that tear film instability is present in almost all contact 
lens wearers with or without symptoms indicating that the 
benefits of Systane® Ultra can apply to asymptomatic as well 
as symptomatic lens wearers.
Moreover, an HP-Guar-containing solution reduced 
aqueous tear evaporation 30 and 60 minutes after applica-
tion in dry eye patients. This antievaporative effect may also 
be achieved in normal eyes when in low relative humidity 
environments32 and may therefore offer further advantages 
to contact lens wearers.
Conclusion
Systane® Ultra is recommended for the temporary relief 
of burning and irritation due to dryness of the eye. Use of 
Systane® Ultra Lubricating Eye Drops in successful contact 
lens wearers was not associated with any significant change 
in corneal staining or distance visual acuity and was not 
associated with any adverse events. While additional clinical 
evaluation should be conducted to further substantiate the 
compatibility of Systane Ultra® in this subject group, this 
clinical study provided evidence of safety and compatibility 
of Systane® Ultra Lubricant Eye Drops in contact lens 
wearers.
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